ZURICH: Swiss drugmaker Novartis is halting its trial of malaria drug hydroxychloroquine (HCQ) against Covid-19 after struggling to find participants, it said, as data emerged from other studies raising doubts about its efficacy.
Novartis’ trial began in April and sought to test the drug in 440 hospitalised patients. But the project only managed to recruit a handful.
Already a subscriber? Log in.
Subscribe to win RM50 Touch 'n Go e-Voucher! More Info
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!